Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.
CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies
Revisit the OncLive On Air Episodes From February 2024
European Commission Approves Cilta-Cel for R/R Myeloma After at Least 1 Prior Line of Therapy
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma
Revisit Every OncLive On Air Episode from March 2024
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma